Growth hormone therapy in Noonan syndrome: growth response and characteristics.

• Growth hormone treatment in Noonan syndrome increases growth velocity significantly during the first 2 years of treatment and, to some extent, until puberty. This increase is more pronounced if treatment is started at an early age. Treatment before the age of 5 years is not recommended due to an increased risk of malignancies. In contrast to other growth hormone-treated patients, a slight but significant further increase in height gain can be expected during pubertal growth (at least in boys). Final height improvement varies between 1 and 2 SDS in different studies. Cardiac function does not seem to be impaired during treatment. No significant adverse events have been reported.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Pediatrik (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Pediatrics (hsv//eng)

Nyckelord

Adolescent

Body Height

Child

Child

Preschool

Female

Growth

Human Growth Hormone

administration & dosage

adverse effects

Humans

Male

Mutation

Noonan Syndrome

drug therapy

genetics

physiopathology

Protein Tyrosine Phosphatase

Non-Receptor Type 11

genetics

Puberty

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)